XML 81 R66.htm IDEA: XBRL DOCUMENT
v3.25.0.1

ACQUISITIONS - Additional Information (Details) - USD ($) $ in Millions |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Feb. 22, 2023 | Sep. 20, 2022 | Jul. 31, 2024 | Mar. 31, 2024 | Oct. 31, 2023 | May 31, 2023 | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  | $ 4,663 | $ 1,155 | $ 944
Stock-based compensation expense |  |  |  |  |  |  | 969 | 796 | 645
Research and development expenses |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  |  |  | 458 | 377 | 285
Selling, general and administrative expenses |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  |  |  | 450 | 361 | 313
CymaBay |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |
Asset acquisition consideration |  |  |  | $ 3,900 |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  | 3,800 |  |
Stock-based compensation expense |  |  |  |  |  |  | 133 |  |
Asset acquisition, assets acquired |  |  |  |  |  |  | 333 |  |
Asset acquisition, liabilities assumed |  |  |  |  |  |  | 228 |  |
Liability payments |  |  |  |  |  |  | 209 |  |
CymaBay | Research and development expenses |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  |  |  | 67 |  |
CymaBay | Selling, general and administrative expenses |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  |  |  | 67 |  |
CymaBay | Janssen Pharmaceutica NV |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |
Payment to extinguish a future royalty obligation |  |  | $ 320 |  |  |  |  |  |
XinThera, Inc |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  | $ 50 |  |  | 170 |
Cash consideration |  |  |  |  |  | $ 200 |  |  |
Maximum potential future milestone payments |  |  |  |  |  | $ 760 |  |  |
Tmunity Therapeutics |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  | 244 |
Cash consideration | $ 300 |  |  |  |  |  |  |  |
Tmunity Therapeutics | Tmunity And University Of Pennsylvania |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  | 47 | $ 25 |
Maximum potential future milestone payments |  |  |  |  |  |  | $ 1,000 |  |
MiroBio Ltd. |  |  |  |  |  |  |  |  |
Business Combination, Separately Recognized Transactions [Line Items] |  |  |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  |  |  |  | $ 389
Cash consideration |  | $ 414 |  |  |  |  |  |  |

X
- Definition Asset Acquisition, Assets Acquired + References No definition available. + Details
Name: | gild_AssetAcquisitionAssetsAcquired
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Asset Acquisition, Liabilities Assumed + References No definition available. + Details
Name: | gild_AssetAcquisitionLiabilitiesAssumed
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Liabilities Assumed, Payment + References No definition available. + Details
Name: | gild_AssetAcquisitionLiabilitiesAssumedPayment
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments For Asset Acquisitions + References No definition available. + Details
Name: | gild_PaymentsForAssetAcquisitions
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments To Extinguish Future Royalty Obligation + References No definition available. + Details
Name: | gild_PaymentsToExtinguishFutureRoyaltyObligation
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Potential Future Milestone Payments, Maximum + References No definition available. + Details
Name: | gild_PotentialFutureMilestonePaymentsMaximum
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=gild_CymaBayMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gild_JanssenPharmaceuticaNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=gild_XinTheraIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=gild_TmunityTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gild_TmunityAndUniversityOfPennsylvaniaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=gild_MiroBioLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |